Skip to main content
Caplight Logo









DermaScan

DermaScan

Private
ParisHealthcare & Life Scienceshttps://www.dermascan.fr/

Last Round

Seed

Feb 2, 2026

Total Funding Raised

$2.96M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

DermaScan is a healthcare company that operates expert centers for skin cancer screening, combining clinical examinations, total body mapping, and technological innovations to provide early detection.

Sector

Healthcare & Life Sciences

Verticals

Clinical Trials, Fashion & Beauty, Biotechnology, Medical Devices, Compliance

Business Model

B2C

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

contract research organizationCROclinical trialscosmetic testingsafety testingefficacy testingclaim substantiationdermo-cosmetic testingin-vivo testingpre-clinical testingin-vitro testingpharmaceutical testingregulatory consultingbiometrologysensory testingmicrobiology testingmedical device testing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DermaScan Comparables

Compare DermaScan with similar companies based on industry and business-model similarity.

DermaScan comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zurko Research
88%
Atlantia Clinical Trials
77%
Eurofins Scientific SE
72%

DermaScan Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 2, 2026

Key People

Founding team and executive leadership

Hadrien Lepage

Co-founder CTO

Founding Team

Florian LEGRIS

Co-founder & CEO

Founding Team

DermaScan Investors

Notable investors and investment history

DermaScan investors
InvestorRounds
Kima VenturesSeed
HexaSeed
TechmindSeed
Ring CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 13, 2026

    Open roles increased from 0 to 4, representing 27% of headcount.

  • Apr 25, 2026

    Grew 36% QoQ, from 11 to 15 employees.

DermaScan Filings

Explore SEC and related filing metadata, where available.

DermaScan filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersParis
Employee Range15
Year Founded2025
Last FundingFeb 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?